[HTML][HTML] Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study
L Rostaing, F Vincenti, J Grinyo, KM Rice… - American journal of …, 2013 - Elsevier
Abstract The Belatacept Evaluation of Nephroprotection and Efficacy as First-line
Immunosuppression Trial randomized patients receiving a living or standard criteria
deceased donor kidney transplant to a more (MI) or less intensive (LI) regimen of belatacept
or cyclosporine A (CsA). The 5-year results of the long-term extension (LTE) cohort are
reported. A total of 456 (68.5% of intent-to-treat) patients entered the LTE at 36 months; 406
patients (89%) completed 60 months. Between Months 36 and 60, death occurred in 2%, 1 …
Immunosuppression Trial randomized patients receiving a living or standard criteria
deceased donor kidney transplant to a more (MI) or less intensive (LI) regimen of belatacept
or cyclosporine A (CsA). The 5-year results of the long-term extension (LTE) cohort are
reported. A total of 456 (68.5% of intent-to-treat) patients entered the LTE at 36 months; 406
patients (89%) completed 60 months. Between Months 36 and 60, death occurred in 2%, 1 …